Generally, BCL-XL and MCL1 mRNA expression was more abundant than BCL-2, which was consistent with the drug screening data showing higher dependency on BCL-XL and MCL-1 in CRC cell lines (Figure 3A–G). The gene discussed is BCL2L1; the disease is colorectal carcinoma.